Cargando…

Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence

Neurodegenerative diseases constitute a broad range of central nervous system disorders, characterized by neuronal degeneration. Alzheimer’s disease, Parkinson’s disease, amyolotrophic lateral sclerosis (ALS), and progressive forms of multiple sclerosis (MS) are some of the most frequent neurodegene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angelopoulou, Efthalia, Pyrgelis, Efstratios-Stylianos, Piperi, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737612/ https://www.ncbi.nlm.nih.gov/pubmed/36500540 http://dx.doi.org/10.3390/molecules27238448

Ejemplares similares

Functional Implications of Protein Arginine Methyltransferases (PRMTs) in Neurodegenerative Diseases
por: Angelopoulou, Efthalia, et al.
Publicado: (2023)

Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury
por: Zhaleh, Mohsen, et al.
Publicado: (2014)

The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease
por: Schwenkgrub, Joanna, et al.
Publicado: (2017)

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
por: Kagitani-Shimono, Kuriko, et al.
Publicado: (2005)

Revisiting the Impact of Neurodegenerative Proteins in Epilepsy: Focus on Alpha-Synuclein, Beta-Amyloid, and Tau
por: Paudel, Yam Nath, et al.
Publicado: (2020)

Emerging Pathogenic and Prognostic Significance of Paired Box 3 (PAX3) Protein in Adult Gliomas
por: Angelopoulou, Efthalia, et al.
Publicado: (2019)

Ibudilast, a Pharmacologic Phosphodiesterase Inhibitor, Prevents Human Immunodeficiency Virus-1 Tat-Mediated Activation of Microglial Cells
por: Kiebala, Michelle, et al.
Publicado: (2011)

Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis
por: Yang, Dongjie, et al.
Publicado: (2020)

Can sars-cov-2 infection exacerbate Alzheimer’s disease? A systematic review
por: Chiara, Villa, et al.
Publicado: (2021)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Arylsulfatase A (ASA) in Parkinson’s Disease: From Pathogenesis to Biomarker Potential
por: Angelopoulou, Efthalia, et al.
Publicado: (2020)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Flotillin: A Promising Biomarker for Alzheimer’s Disease
por: Angelopoulou, Efthalia, et al.
Publicado: (2020)

Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review
por: Angelopoulou, Efthalia, et al.
Publicado: (2022)

Radiosynthesis and Preclinical Evaluation of an (18)F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)
por: Wenzel, Barbara, et al.
Publicado: (2022)

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
por: Zhang, Wen-Hao, et al.
Publicado: (2016)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities
por: Paudel, Yam Nath, et al.
Publicado: (2020)

Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson’s Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology
por: Angelopoulou, Efthalia, et al.
Publicado: (2020)

Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches
por: Degirmenci, Yildiz, et al.
Publicado: (2023)

Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra
por: Rahardjo, Harrina E, et al.
Publicado: (2021)

Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
por: Paudel, Yam Nath, et al.
Publicado: (2020)

From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod
por: Paudel, Yam Nath, et al.
Publicado: (2020)

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
por: Rybalkina, Irina G, et al.
Publicado: (2011)

Signal Transduction of Improving Effects of Ibudilast on Methamphetamine Induced Cell Death
por: Tahvilian, Reza, et al.
Publicado: (2019)

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype
por: Goodman, Andrew D., et al.
Publicado: (2021)

Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson’s Disease
por: Angelopoulou, Efthalia, et al.
Publicado: (2023)

Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review
por: Angelopoulou, Efthalia, et al.
Publicado: (2023)

Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis-induced Acute Kidney Injury
por: Xu, Xingkai, et al.
Publicado: (2020)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells
por: Dong, Hongli, et al.
Publicado: (2013)

Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders
por: Mishra, Awanish, et al.
Publicado: (2021)

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
por: Chang, Jo-Fan, et al.
Publicado: (2019)

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
por: Ha, Wendy, et al.
Publicado: (2019)

Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
por: Niu, Miaomiao, et al.
Publicado: (2013)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
por: Shafiee, Arman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6pi7ac2u2kgihfjnsd32c3397t